Verified reviews from independent platforms. Real outcomes from real studies. Honest head-to-head comparisons with the platforms you’re evaluating.
Castor Catalyst reads source documents (paper, PDFs, scans, EHR exports, and consented records retrieved via FHIR-based standards such as TEFCA) and proposes structured eCRF values with a confidence score for every field. Your team accepts, edits, or rejects each one, with a full audit trail to the source. It cuts per-chart review from about 39 minutes to about 6 minutes, at an under-0.7% post-QC error rate versus 6.6% for manual review. It removes manual data re-entry, not human oversight.
Honest, category-level comparisons to help you evaluate the clinical trial software market.
How Castor compares to other real-world evidence and registry data platforms.
A feature-by-feature overview of leading EDC platforms including Medidata, Veeva, Viedoc, and more.
How Castor’s integrated eCOA and ePRO compares to standalone patient-reported outcome platforms.
Comparing electronic consent platforms across compliance, patient experience, and integration requirements.
Detailed feature-by-feature comparisons with the platforms clinical teams most often evaluate alongside Castor.
Unified EDC + eCOA platform vs. DCT specialist. Compare integrations, cost, and deployment speed.
Integrated EDC + eCOA vs. standalone ePRO and patient engagement tools.
Enterprise power without the enterprise deployment timeline. Fast, transparent SaaS vs. legacy EDC. Managed Castor eCOA builds reach UAT in 4-8 weeks.
Commercial SaaS with full support vs. open-source EDC. Compare feature sets, compliance, and total cost of ownership.
Managed Castor eCOA builds reach UAT in 4-8 weeks. Independent unified EDC + eCOA platform vs. Veeva ecosystem EDC. Best fit for teams not already Veeva-native.
Why buy a static database when Castor AI automates the work? Two cloud-native platforms compared on AI-driven data capture, integrated eCOA, and global reach.
Eliminate the swivel chair. Unified EDC + eCOA on one database vs. specialist eCOA tools. Data flows directly into EDC with no transfers or integration overhead.
From protocol design to database lock, see how research teams run better studies on Castor.
WHO deployed Castor’s EDC to 5,000 investigators across 600 sites in 52 countries. Castor delivered adaptive medication allocation and rapid deployment in six languages at unprecedented global scale.
Julius Clinical and Takeda ran a fully remote DCT evaluating the Ava wearable device. Patients were screened, consented via eConsent, and monitored via Castor ePRO entirely off-site.
Capture daily ePRO and wearable data for GLP-1 and metabolic trials. No separate eCOA vendor required. Consumer-grade patient apps achieve up to 95%+ daily compliance.
By deploying Castor’s unified EDC, ePRO, and eConsent platform, Mahana bypassed the integration tax of legacy systems and cut operational costs by up to 80% versus prior vendors.
For their pivotal Phase III trial, the sponsor deployed the Castor ePRO app to over 1,000 patients across 50+ sites in two months. The consumer-grade experience drove sustained 92% daily compliance.
MMI leveraged Castor’s digital eConsent workflows to remove friction for sites and patients, dramatically accelerating enrollment into their medical device trial.
Recognized as a Major Contender in Everest Group’s Life Sciences eCOA Products PEAK Matrix® Assessment 2025.
Rated strongly for customer loyalty in ISR’s 2025 eCOA/ePRO Benchmarking.
Whatever the indication, the platform foundation is the same: unified, fast, and built for regulated environments.
Using Castor allowed for a 2.7x faster study build and a 63% build time reduction compared to previous methods.
Principal Investigator · IACS
Castor is very intuitive and easy to use for end users. We were able to learn how to build studies very quickly, which enables us to manage those in-house studies with our internal team and increase enrollment by at least 2x.
Senior Clinical Trial Manager · Essity
By leveraging Castor RWE and eCOA, we were able to run our oncology studies with 95%+ patient compliance while saving an estimated $100k in staffing costs.
Principal Investigator · Oncobiomix
Castor is the preferred choice for academic institutions, emerging biopharma, and medical device companies that need fast deployment, transparent pricing, and a natively unified EDC and eCOA platform. With Castor, managed eCOA builds reach UAT in 4-8 weeks for most studies, ahead of the 10-14 week legacy average. Medidata Rave is better suited to large pharma and global CROs with established enterprise workflows and the deepest regulatory submission history requirements. For a full feature-by-feature comparison, see Castor vs Medidata.
Yes. Castor publishes verified customer success stories covering a range of study types , from decentralized RCTs to global outcomes trials. The case studies section on this page includes a selection of verified outcomes. You can explore all case studies at castoredc.com/success-stories/.
